Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Data

Cancers·BRCA or PALB2-mutant pancreatic ductal adenocarcinoma

DataBRCA or PALB2-mutant pancreatic ductal adenocarcinoma

Back to the BRCA or PALB2-mutant pancreatic ductal adenocarcinoma hub →77 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

77

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Shares Diane M. Simeone, Familial pancreatic cancer and inherited risk (who qualifies for surveillance), PRODIGE 24 / CCTG PA6, High-risk pancreatic surveillance (CAPS / PRECEDE) and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Pancreatic acinar cell carcinoma, Pancreatic cancer (KEGG map), Neoadjuvant / adjuvant / perioperative, Resectable pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Locally advanced unresectable pancreatic ductal adenocarcinoma
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Eileen M. O'Reilly, Daraxonrasib, Pancreatic cancer (KEGG map) and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Germline (hereditary) testing, KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares KRAS, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares KRAS, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.
Cancer
Metastatic and recurrent anal squamous cell carcinoma
Shares Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.
Cancer
Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei
Shares KRAS and the tags subtype-page, gastrointestinal.

technologies

Cytotoxic chemotherapy Germline (hereditary) testing High-risk pancreatic surveillance (CAPS / PRECEDE)Immune checkpoint inhibitors KRAS & RAS inhibitors Liquid biopsy (ctDNA)PARP inhibitors Platinum agents Topoisomerase-I inhibitors (and ADC payloads)

targets

BRCA1 / BRCA2 (HRD)CTLA-4 KRAS PARP

drugs

ApprovedCytotoxic chemotherapy (platinum)

Cisplatin · Platinol (generic)

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedCytotoxic regimen

Gemcitabine + cisplatin

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedMonoclonal antibody (anti-CTLA-4)

Ipilimumab · Yervoy

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

ApprovedSmall-molecule PARP inhibitor

Niraparib · Zejula

ApprovedSmall-molecule PARP inhibitor

Olaparib · Lynparza

ApprovedSmall-molecule PARP inhibitor

Rucaparib · Rubraca

ApprovedSmall-molecule PARP inhibitor

Talazoparib · Talzenna

companies

AstraZeneca Bristol Myers Squibb GSK Ipsen Merck & Co. (MSD)Pfizer (incl. Seagen)pharma&Revolution Medicines

pathways

DNA damage response & homologous recombination Double-strand break repair: HR versus end joining Pancreatic cancer (KEGG map)Synthetic lethality: paired dependencies

terms

BRCA reversion mutations Drug resistance (primary and acquired)Familial pancreatic cancer and inherited risk (who qualifies for surveillance)Germline BRCA mutation (gBRCA)Germline vs somatic mutations Homologous recombination deficiency (HRD)Neoadjuvant / adjuvant / perioperative Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)Platinum-sensitive / platinum-resistant

trials

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency POLO PREOPANC-1 PRODIGE 24 / CCTG PA6 Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

roadmaps

Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question

ideas

Automatic germline testing for every cancer type where it changes care Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception

people

Bert Vogelstein Diane M. Simeone Eileen M. O'Reilly Susan M. Domchek Talia Golan

key papers

Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2 POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms Whole genomes redefine the mutational landscape of pancreatic cancer

biomarkers

Germline BRCA1/2 pathogenic variant (gBRCAm)HRD-positive (genomic instability score)Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-22 · Jude Gomila · Every pancreatic subtype page now rests on two to four la… · diff · file

Wikipedia

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of BRCA or PALB2-mutant pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/brca-palb2-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id brca-palb2-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.